Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Organogenesis Holdings (ORGO) Shares Outstanding (2016 - 2026)

Organogenesis Holdings has reported Shares Outstanding over the past 11 years, most recently at $127.7 million for Q4 2025.

  • For Q4 2025, Shares Outstanding rose 0.97% year-over-year to $127.7 million; the TTM value through Dec 2025 reached $127.7 million, up 0.97%, while the annual FY2025 figure was $127.7 million, 0.97% up from the prior year.
  • Shares Outstanding for Q4 2025 was $127.0 million at Organogenesis Holdings, down from $127.6 million in the prior quarter.
  • Over five years, Shares Outstanding peaked at $132.6 million in Q3 2024 and troughed at $126.5 million in Q4 2024.
  • A 5-year average of $129.6 million and a median of $129.9 million in 2022 define the central range for Shares Outstanding.
  • Biggest five-year swings in Shares Outstanding: increased 21.69% in 2021 and later decreased 4.32% in 2025.
  • Year by year, Shares Outstanding stood at $128.7 million in 2021, then rose by 1.74% to $130.9 million in 2022, then rose by 0.3% to $131.3 million in 2023, then decreased by 3.7% to $126.5 million in 2024, then grew by 0.97% to $127.7 million in 2025.
  • Business Quant data shows Shares Outstanding for ORGO at $127.7 million in Q4 2025, $126.9 million in Q3 2025, and $126.9 million in Q2 2025.